Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

Yao Zhao; Chao Fang; Qi Zhang; Ruxue Zhang; Xiangbo Zhao; Yinkai Duan; Haofeng Wang; Yan Zhu; Lu Feng; Jinyi Zhao; Maolin Shao; Xiuna Yang; Leike Zhang; Chao Peng; Kailin Yang; Dawei Ma; Zihe Rao; Haitao Yang

doi:10.1007/s13238-021-00883-2

PDF(749 KB)

Protein Cell ›› 2022, Vol. 13 ›› Issue (9) : 689-693. DOI: 10.1007/s13238-021-00883-2

LETTER

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

Yao Zhao¹ ,
Chao Fang² ,
Qi Zhang¹^,³^,⁴ ,
Ruxue Zhang⁵ ,
Xiangbo Zhao² ,
Yinkai Duan¹ ,
Haofeng Wang¹ ,
Yan Zhu¹ ,
Lu Feng¹ ,
Jinyi Zhao¹ ,
Maolin Shao¹ ,
Xiuna Yang¹ ,
Leike Zhang⁵ ,
Chao Peng⁶ ,
Kailin Yang⁷ ,
Dawei Ma² ,
Zihe Rao¹^,⁸^,⁹ ,
Haitao Yang¹

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Yao Zhao, Chao Fang, Qi Zhang, Ruxue Zhang, Xiangbo Zhao, Yinkai Duan, Haofeng Wang, Yan Zhu, Lu Feng, Jinyi Zhao, Maolin Shao, Xiuna Yang, Leike Zhang, Chao Peng, Kailin Yang, Dawei Ma, Zihe Rao, Haitao Yang. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell, 2022, 13(9): 689‒693 https://doi.org/10.1007/s13238-021-00883-2

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H et al (2021) Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19. BbioRxiv 1: 2020- 2029

[2]	Cui W, Yang K, Yang H (2020) Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19. Front Mol Biosci 7: 616341 CrossRef Google scholar

[3]	Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F et al (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368: 1331- 1335 CrossRef Google scholar

[4]	Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P et al (2020) Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11: 4417 CrossRef Google scholar

[5]	Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY et al (2020) Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem 63: 12725- 12747 CrossRef Google scholar

[6]	Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582: 289- 293 CrossRef Google scholar

[7]	Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, Abeles SR, Torriani FJ (2021) Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med 384: 1774- 1775 CrossRef Google scholar

[8]	Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565- 574 CrossRef Google scholar

[9]	Manns MP, von Hahn T (2013) Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12: 595- 610 CrossRef Google scholar

[10]	Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF (2021) Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 21: 626- 636 CrossRef Google scholar

[11]	Vandyck K, Deval J (2021) Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol 49: 36- 40 CrossRef Google scholar

[12]	Wang F, Chen C, Tan W, Yang K, Yang H (2016) Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci Rep 6: 22677 CrossRef Google scholar

[13]	Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J et al (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3: e324 CrossRef Google scholar

[14]	Zhao Y, Du X, Duan Y, Pan X, Sun Y, You T, Han L, Jin Z, Shang W, Yu J et al (2021) High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell https://doi.org/10.1007/s13238-021-00836-9

[15]	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054- 1062 CrossRef Google scholar